Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) and 10x Genomics (NASDAQ:TXG – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.
Profitability
This table compares Valion Bio, Inc. Common Stock and 10x Genomics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Valion Bio, Inc. Common Stock | N/A | -138.10% | -63.67% |
| 10x Genomics | -3.55% | -2.86% | -2.23% |
Analyst Recommendations
This is a summary of recent ratings and target prices for Valion Bio, Inc. Common Stock and 10x Genomics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Valion Bio, Inc. Common Stock | 1 | 0 | 0 | 0 | 1.00 |
| 10x Genomics | 1 | 10 | 4 | 0 | 2.20 |
Valuation and Earnings
This table compares Valion Bio, Inc. Common Stock and 10x Genomics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Valion Bio, Inc. Common Stock | $780,000.00 | 3.14 | -$8.88 million | ($6.68) | -0.11 |
| 10x Genomics | $642.82 million | 5.59 | -$43.54 million | ($0.17) | -166.53 |
Valion Bio, Inc. Common Stock has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Valion Bio, Inc. Common Stock has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500.
Institutional and Insider Ownership
4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 14.5% of Valion Bio, Inc. Common Stock shares are owned by company insiders. Comparatively, 8.8% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
10x Genomics beats Valion Bio, Inc. Common Stock on 10 of the 14 factors compared between the two stocks.
About Valion Bio, Inc. Common Stock
Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
About 10x Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Receive News & Ratings for Valion Bio Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valion Bio Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
